D-1092-2023 Class II Terminated
FDA drug recall D-1092-2023 was initiated by Parker Laboratories, Inc. on Aug 2, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Jun 3, 2024). Affected quantity: 40.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 30, 2023
- Initiation Date
- Aug 2, 2023
- Termination Date
- Jun 3, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 40
Product description
Helix CBD Therapy Cream (Menthol 7.4%), packaged in a) 3 g pouch (NDC 30775-053-01), b) 2 fl. oz. tubes (NDC 30775-053-02), c) 4 fl. oz. tubes (NDC 30775-053-04), Parker Laboratories Inc., Fairfield, NJ, 07004
Reason for recall
CGMP Deviations
Distribution pattern
Nationwide within the United States, Singapore, Korea and Hong Kong
Code information
Lot #: a) J1121010, Exp. Date 12/16/2023, b) A0921006, Exp. Date 8/16/2023, c) A0921007, Exp. Date 8/16/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1092-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026